Arrowhead Pharmaceuticals, Inc.
Bear Case (25th pct.)
-120.5% vs price
Base Case (Median)
-95.9% vs price
Bull Case (75th pct.)
-91.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-40.00 | -145.1% | High (40%) |
| EV/EBITDA | $12.32 | -86.1% | Medium (20%) |
| Earnings Power Value | $3.64 | -95.9% | Medium (50%) |
Based on 3 out of 8 methods, ARWR appears overvalued at the current price of $88.70. The base case fair value of $3.64 implies 95.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.